A Study of LY4268989 (MORF-057) in Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
144actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-01 | actual | When the study began enrolling |
| Primary completion | 2026-02-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: LY4268989
- Drug: Placebo
- Drug: Midazolam
- Drug: Midazolam
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5)
measured Day 1 to Day 17
PK: Area Under the Concentration Curve (AUC) of LY4268989 (Cohort 1) and (Cohort 5)
measured Day 1 to Day 17
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Cohort 1), (Cohort 3), and (Cohort 5)
measured Baseline to Study Completion (Up to Day 17)
Number of Participants with TEAEs and SAEs (Cohort 4)
measured Baseline to Study Completion (Up to Period 4, Day 4)
PK: Cmax of LY4268989 (Cohort 2)
measured Day 1 to Day 13
PK: AUC of LY4268989 (Cohort 2)
measured Day 1 to Day 13
PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 3)
measured Day 1 to Day 17
PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 8)
measured Day 3 and Day 11
PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 3)
measured Day 1 to Day 17
PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 8)
measured Day 3 to Day 11
PK: Cmax of LY4268989 (Cohort 6)
measured Day 1 to Day 7
PK: AUC of LY4268989 (Cohort 6)
measured Day 1 to Day 7
PK: Cmax of LY4268989 (Cohort 7)
measured Day 1 to Day 12
PK: AUC of LY4268989 (Cohort 7)
measured Day 1 to Day 12
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed